Remi Therapeutics is pioneering breakthrough treatments that offer new hope to individuals with autism and their families. Through their innovative first-in-class therapies, the company is addressing critical unmet needs in autism care, targeting a community that has long been underserved by traditional pharmaceutical approaches.
Led by an experienced management team with deep expertise in neurodevelopmental disorders, Remi is developing therapeutic solutions that have the potential to meaningfully improve quality of life for those on the autism spectrum.
This comprehensive approach recognizes the complexity of autism and focuses on creating treatments that can make a real difference in the daily lives of patients and their caregivers, representing a significant step forward in autism therapeutics.
Despite autism affecting 1 in 31 children in the U.S. and imposing an estimated $1 trillion (by 2030) annual economic burden, there are no FDA-approved treatments specifically targeting the core symptoms of Autism.
Right now, families dealing with autism face a major problem: there are no medicines made specifically for autism's main symptoms. This means doctors have to use medicines created for other conditions. Giving a child three or four different pills that were made for depression, ADHD, or sleep problems with the hope they might help with autism symptoms does not always address the symptoms. It's like trying to fix a computer with tools made for a car.
This creates a huge opportunity for companies developing targeted autism therapies to capture a market where families are desperate for solutions that actually work. The challenge gets even bigger when you look at how different autism can be from person to person.
Right now, the spectrum of symptoms lead many doctors to treat everyone the same way, but that's like giving everyone the same shoe size. It just doesn't fit most people.
These problems make it hard for kids to do everyday things like go to school, make friends, or just be independent. Families spend huge amounts of money and time trying different medicines that often cause bad side effects like weight gain and feeling tired all the time, without really fixing what's wrong in the brain.
There is a clear gap in the market where targeted, symptom-specific treatments could transform millions of lives in a field crying out for change.
Remi Therapeutics is pioneering a new approach to treating autism through first-in-class therapies that target specific underlying pathologies rather than just managing symptoms. Our strategy leverages novel mechanisms of action with strong intellectual property protection, backed by extensive preclinical validation including improved cognition and addressing key pathologies identified by leading autism researchers like Dr. Jill James and Dr. Carl Nathan.
We have mitigated risk through a diversified portfolio of three independent assets targeting different patient subpopulations within the autism spectrum, with clear expansion opportunities beyond autism into broader markets.
This innovative platform approach is led by an experienced management team with over 30 years of pharmaceutical expertise, including CEO Brian Groch who has raised over $125 million and launched 30 products, supported by leadership with proven track records at major pharmaceutical companies like Pfizer, Merck, and Novartis, providing deep expertise in CNS drug development and commercialization.
RT0307 is being developed to help people with Autism by improving thinking, behavior, and social interaction which are core challenges for families today.
It combines three powerful approaches in one therapy:
Learn More
RT8412 is being developed to boost focus and memory by targeting brain inflammation.
RT2234 is being developed to help people with Autism by improving thinking, behavior, and social interaction which are core challenges for families today.
RT2234 has the potential to attack Alzheimer's disease by fighting both brain inflammation and cell damage at the same time. The drug combines two medicines that work together - one calms down harmful brain swelling while the other protects brain cells from breaking down. Preclinical studies show it helps cognition and protects brain cells from the toxic proteins that cause Alzheimer's. Small human studies already show older adults can think faster after taking part of this treatment. This two-way approach could slow down or even stop Alzheimer's from getting worse, not just treat the symptoms.
Popular weight loss drugs like Ozempic help people lose weight, but they also cause dangerous muscle loss. RT2234 may solve this problem by protecting and building muscle while people use these weight loss treatments. The weight loss drug market will be worth $200 billion by 2031, and about $60 billion of that will need muscle protection treatments. If RT2234 captures just 15% of this new market, it could generate $9 billion in sales. This is a huge opportunity because millions of people are starting these weight loss drugs but need a way to keep their muscle strength and health.
The global autism market presents an extraordinary investment opportunity, with the treatment drugs sector alone valued at $4.5 billion in 2024 and projected to nearly double to $8.2 billion by 2033, representing a robust 8.2% compound annual growth rate.
The clinical complexity of autism creates multiple therapeutic targets and revenue streams, as patients commonly present with additional conditions that demand comprehensive treatment approaches. With 70% of autism patients also having ADHD, 50% experiencing muscle wasting, and 40% facing cognitive challenges, there is a massive opportunity to address these issues concurrently.
As awareness continues to drive earlier diagnosis and intervention, companies entering this space now are positioned to capitalize on both the expanding patient population and the critical unmet medical needs within the autism community.
For too long, autism care has relied on drugs that mute behaviors but don’t help the person behind them. Children are handed medications that sedate, suppress, and dull—offering temporary quiet at the cost of cognition, emotion, and connection.
At Remi Therapeutics, we believe autism is not a simple behavioral problem. It’s a biological condition—driven by neuroinflammation, oxidative stress, and dysfunctional neural signaling. And biology can be treated.
Our therapies are designed to restore what’s possible: clearer thinking, calmer emotions, stronger focus, and greater independence. Our assets address the core drivers of behaviourial dysregulation: neurotransmitter imbalance, neuroinflammation and redox-driven cellular stress. It’s built for the real-world struggles of people and families managing a life touched by autism
We’re building Remi for the families who have waited too long. For the kids who deserve more than sedation. For the adults with autism who still live in systems that misunderstand them.
Now, we’re inviting you to join us.
This isn’t just drug development. It’s a mission to transform autism care by healing the brain and restoring their future.